Gender-related differences in the outcome of patients with venous thromboembolism and thrombophilia

      This paper is only available as a PDF. To read, Please Download here.

      ABSTRACT

      Background

      In patients with venous thromboembolism (VTE) and factor V Leiden (FVL) or prothrombin 20210 G-A mutation (PTM), the influence of gender on outcome has not been consistently studied.

      Methods

      We used the RIETE (Registro Informatizado Enfermedad TromboEmbolica) database to assess the existence of gender differences in the rate of VTE recurrences (deep vein thrombosis [DVT] or pulmonary embolism [PE]) or major bleeding during the course of anticoagulation and after its discontinuation in FVL and PTM carriers.

      Results

      From March 2001 to September 2016, 11,224 VTE patients underwent thrombophilia testing. Of these, 1,563 were FVL carriers (863 men and 700 women) and 1,231 were PTM carriers (659 men and 572 women). During the course of anticoagulant therapy, men with FVL had a 6-fold higher rate of VTE recurrences than major bleeds (31 vs. 5 events). In women with FVL, the rate of VTE recurrences was 2-fold higher (16 vs. 8), as was in men (17 vs. 8) or women (17 vs. 9) with PTM. After discontinuing anticoagulation, men with FVL had a 3-fold higher rate of DVT recurrences than women (hazard ratio [HR]: 3.13; 95% CI: 1.79–5.67), with no differences in PE recurrences. Among patients with PTM, there were no gender differences in the rate of DVT (HR: 1.89; 95% CI: 1.00–3.65) or PE recurrences (HR: 1.82; 95% CI: 0.83–4.12).

      Conclusions

      During the anticoagulation course, men with FVL are at a much higher risk for VTE recurrences than bleeding. After discontinuing anticoagulation, men with FVL are at an increased risk for DVT recurrences.

      Keywords

      To read this article in full you will need to make a payment
      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Herrmann F.H.
        • Koesling M.
        • Schroder W.
        • Altman R.
        • Jimenez Bonilla R.
        • Lopaciuk S.
        • et al.
        Prevalence of factor V Leiden mutation in various populations.
        Genet Epidemiol. 1997; 14: 403-411
        • Poort S.R.
        • Rosendaal F.R.
        • Reitsma P.H.
        • Bertina R.M.
        A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.
        Blood. 1996; 88: 3698-3703
        • Tzoran I.
        • Papadakis M.
        • Brenner B.
        • Fidalgo A.
        • Rivas A.
        • Wells P.S.
        • et al.
        Outcome of patients with venous thromboembolism and Factor V Leiden or Prothrombin 20210 carrier mutations during the course of anticoagulation.
        Am J Med. 2016;
        • Segal J.B.
        • Brotman D.J.
        • Necochea A.J.
        • Emadi A.
        • Samal L.
        • Wilson L.M.
        • et al.
        Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review.
        JAMA. 2009; 301: 2472-2485
        • Marchiori A.
        • Mosena L.
        • Prins M.H.
        • Prandoni P.
        The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.
        Haematologica. 2007; 92: 1107-1114
        • Roldan V.
        • Lecumberri R.
        • Munoz-Torrero J.F.
        • Vicente V.
        • Rocha E.
        • Brenner B.
        • et al.
        Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry.
        Thromb Res. 2009; 124: 174-177
        • Blanco-Molina A.
        • Enea I.
        • Gadelha T.
        • Tufano A.
        • Bura-Riviere A.
        • Di Micco P.
        • et al.
        Sex differences in patients receiving anticoagulant therapy for venous thromboembolism.
        Medicine (Baltimore). 2014; 93: 309-317
        • Nieto J.A.
        • Solano R.
        • Ruiz-Ribo M.D.
        • Ruiz-Gimenez N.
        • Prandoni P.
        • Kearon C.
        • et al.
        Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry.
        J Thromb Haemost. 2010; 8: 1216-1222
        • Munoz-Torrero J.F.
        • Bounameaux H.
        • Pedrajas J.M.
        • Lorenzo A.
        • Rubio S.
        • Kearon C.
        • et al.
        Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis.
        J Vasc Surg. 2011; 54: 26S-32S
        • Ruiz-Gimenez N.
        • Suarez C.
        • Gonzalez R.
        • Nieto J.A.
        • Todoli J.A.
        • Samperiz A.L.
        • et al.
        Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry.
        Thromb Haemost. 2008; 100: 26-31
        • Baglin T.
        • Luddington R.
        • Brown K.
        • Baglin C.
        High risk of recurrent venous thromboembolism in men.
        J Thromb Haemost. 2004; 2: 2152-2155
        • Christiansen S.C.
        • Lijfering W.M.
        • Helmerhorst F.M.
        • Rosendaal F.R.
        • Cannegieter S.C.
        Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event.
        J Thromb Haemost. 2010; 8: 2159-2168
        • Kyrle P.A.
        • Minar E.
        • Bialonczyk C.
        • Hirschl M.
        • Weltermann A.
        • Eichinger S.
        The risk of recurrent venous thromboembolism in men and women.
        N Engl J Med. 2004; 350: 2558-2563
        • Tagalakis V.
        • Kondal D.
        • Ji Y.
        • Boivin J.F.
        • Moride Y.
        • Ciampi A.
        • et al.
        Men had a higher risk of recurrent venous thromboembolism than women: a large population study.
        Gend Med. 2012; 9: 33-43
        • Lijfering W.M.
        • Veeger N.J.
        • Middeldorp S.
        • Hamulyak K.
        • Prins M.H.
        • Buller H.R.
        • et al.
        A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families.
        Blood. 2009; 114: 2031-2036
        • Kearon C.
        • Akl E.A.
        • Ornelas J.
        • Blaivas A.
        • Jimenez D.
        • Bounameaux H.
        • et al.
        Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.
        Chest. 2016; 149: 315-352
        • Baglin T.
        • Luddington R.
        • Brown K.
        • Baglin C.
        Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.
        Lancet. 2003; 362: 523-526
        • Palareti G.
        • Legnani C.
        • Cosmi B.
        • Valdre L.
        • Lunghi B.
        • Bernardi F.
        • et al.
        Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
        Circulation. 2003; 108: 313-318